Document:

<PAGE>   1

                                                                   EXHIBIT 10.15

                                SUPPLY AGREEMENT

This Supply Agreement ("Agreement") is entered into on this 25th day of May,
2000 by and between

LIFE SCIENCES INC., (hereinafter referred to as "LSI"), a corporation
established under the laws of Delaware, having its registered offices at 2900
72nd Street North, St. Petersburg, Florida 33710, U.S.A.,

and

ORGANON TEKNIKA B.V. (hereinafter referred to as "Teknika"), a private company
with limited liability incorporated under the laws of The Netherlands, having
its principal place of business at Boseind 15, 5281 RM Boxtel, The Netherlands,

WITNESSETH

That, Teknika wishes to purchase and LSI wishes to supply certain products of
LSI manufactured for Teknika for the purposes of incorporating these products
into a diagnostic test kit for the sale of such test kit in the whole world;

NOW, THEREFORE, in consideration of the mutual promises and undertakings of the
parties hereinafter set forth, and for other good and valuable consideration;
the receipt and sufficiency of which are hereby acknowledged, it is agreed by
and between the parties as follows:

Art. 1. Definition

The term "Affiliate" means any company or other business entity which, by means
of ownership of a majority of shares or at least 50% interest in income or
otherwise, directly or indirectly controls, is controlled by or is under common
control with either party.

The term "Effective Date" shall mean the day, month and year set out above.

The term "Products" means the NASBA Enzyme Cocktails which includes T7 RNA
Polymerase in glycerol free medium, AMV-Reverse Transcriptase in glycerol free
medium and E.coli RNase H in glycerol free medium which are individually
packaged components according to the Specifications in Appendix I, which
Appendix can be modified by mutual agreement from time to time.

Art. 2. Distribution Rights

LSI agrees to supply Teknika with the Products for further manufacturing use by
Teknika in the production of in vitro diagnostics products (e.g., NucliSens) to
be distributed and sold worldwide.

1
<PAGE>   2

Art. 3. Supply of Products

3.1.     LSI undertakes to supply non exclusively to Teknika during the term of
         this Agreement, the Products and Teknika agrees to purchase the
         Products on a non-exclusive basis from LSI, provided, however, that LSI
         meets all of Teknika's quality, logistical, and commercial needs
         outlined in this Agreement.

3.2.     Where a supply agreement is concluded by LSI with a third party for the
         supply of the Products and/or products comparable to the Products on
         equal or more favourable terms and conditions than those of this Supply
         Agreement, and/or at a price which is lower than the price applicable
         at the time for Teknika, Teknika shall promptly be informed thereof and
         shall (as of the date of the third party supply agreement and/or of the
         date such lower price was effected) be entitled to more favourable
         terms and conditions and/or lower prices than those granted
         respectively or offered to such third party.

Art. 4. Prices and Terms

4.1.     Product will be supplied by LSI to Teknika at prices as specified in
         Appendix II. Prices of the cocktail as a whole and also the individual
         component prices are to be communicated.

4.2.     The prices specified in Appendix II shall be valid until January first
         2003.

4.3.     Price increases and decreases due to specification (Appendix I)
         changes can be implemented after written approval of Teknika's
         International Purchasing Department.

4.4.     Price increases will not affect purchase orders which are already
         placed by Teknika.

4.5.     LSI shall have the right to renegotiate prices based on specification
         changes or significant changes in the price of raw materials. In the
         event of a significant change in raw material prices, LSI will inform
         Teknika, in writing, of any corresponding price increase thirty (30)
         days in advance, and will provide appropriate documentation of the raw
         material cost increase. For purposes of this Agreement, a "significant
         change" in raw material prices will be any change greater than or
         equal to five percent (5%) of total raw material costs, whether
         occurring in a single price increase or several over time.

4.6.     Although prices can be reviewed yearly, it is the objective of LSI to
         be competitive in the market of pharmaceutical industry and to seek
         better ways to improve efficiency and to lower prices of products.

4.7.     Parties will meet every October to discuss and review forecasts, to
         discuss general market conditions, the parties' collaboration under
         this Agreement

2

<PAGE>   3

     and the conditions that have consequences for the parties in the execution
     of this Agreement.

Art. 5. Delivery and payment conditions

All purchases made by Teknika from LSI hereunder shall be subject to the
following conditions of delivery:

5.1.  Teknika shall be invoiced by LSI for all purchases made by Teknika. Terms
      shall be net 45 days after date of delivery. A 1.5% discount on invoice
      prices will be applicable for payment received within 15 days.

5.2.  LSI shall deliver Product furnished with the necessary labels.

5.3.  All deliveries, unless otherwise specified by Teknika, shall be Ex Works
      St. Petersburg, Florida, USA (Incoterms 1990).

5.4.  Invoices will be paid in U.S. dollars.

5.5.  Rejected Products (i.e. Products which do not meet Appendix I
      specifications), will be free of charge replaced by LSI within one (1)
      month after receipt of written complaint, provided such written complaint
      is submitted to LSI within 30 days after arrival of the Products at
      Teknika's premises. Parties agree that, in such an event, calamity lead
      time is defined and will be 4 calendar weeks. For the avoidance of doubt
      the costs of transport for the return of rejected Products are for the
      account of LSI.

Art. 6. Product manufacture and product changes

6.1.  LSI shall inform Teknika about any improvements or new developments with
      respect to the Products. However, LSI shall not make any changes and/or
      modifications to the Products without first obtaining Teknika's prior
      written approval.

6.2.  Teknika has the right upon reasonable prior notice and under
      confidentiality to inspect the manufacture and quality control procedures
      of LSI relating to the Products.

6.3.  Minor changes not affecting form, fit or function required to keep the
      Products within specifications shall be permitted. Changing raw materials
      or raw material vendors may not be done without Teknika's written
      approval.

Art. 7. Warranties

3
<PAGE>   4
7.1.    LSI warrants that the Products will meet the specifications set forth in
        Appendix I (some of which specifications may be amended from time to
        time by mutual consent). LSI warrants that it will supply, under this
        Agreement, Products that will be of first class commercial quality,
        properly packed, manufactured of proper materials meeting the
        specifications accompanied with a Certificate of Conformity with each
        shipment and that they are manufactured in compliance with Good
        Manufacturing Practice Regulations.

7.2.    LSI furthermore warrants that, to the best of LSI's knowledge, the
        development and manufacture of the Products by LSI does not infringe any
        intellectual property rights or other proprietary rights of a third
        party.

Art. 8. Orders-orderplan-forecasts

8.1.    Teknika shall provide LSI with a written forecast of its best estimate
        of requirements of the Products for each twelve (12) forthcoming
        calendar months and shall update such forecast on quarterly basis, which
        update should be available at LSI at least one calendar week before the
        start of the new quarter.

8.2.    The first three months of the forecast will be accompanied by firm
        purchase orders.

8.3.    LSI will confirm all Teknika purchase orders within ten (10) working
        days as from the day of receipt of the purchase order, to Teknika's
        International Purchasing Department. Confirmation may be made by fax.

8.4.    LSI only can ship orders when confirmed in writing by Teknika and when a
        purchase order number has been submitted by Teknika's International
        Purchasing Department.

8.5.    Teknika's purchase cycles divide a year into ten (10) periods of
        essentially thirty-six (36) days each. These time divisions ("Purchase
        Periods") are used in this Agreement for measuring and describing LSI's
        supply obligations with respect to Products under this Agreement and
        Teknika's purchase obligations of Products under this Agreement.

8.6.    Promptly after the Effective Date, Teknika shall issue to LSI an extra
        purchase order to build up an adequate buffer stock. The amount of
        Products ordered through this stock purchase order will be comparable to
        three (3) months requirements of Products as communicated with the
        twelve (12) months rolling forecast provided by the Effective Date of
        this Agreement.

Art. 9. Supply and Quality Assurance

9.1.    LSI shall meet all quality, safety and environmental requirements for
        the manufacturing and delivery of Products as described in Appendix I.
        (See

4
<PAGE>   5
        stands in exhibit I, stand 72237 Rev:00, stand 72239 Rev:00, stand 72236
        Rev:01.)

9.2.    LSI will secure its supply of raw material if applicable in adequate
        quantities at all times to reach Teknika's Product requirements, from
        at least two legitimate suppliers. LSI is also capable to deliver from
        a second manufacturing site if necessary.

        The objective of LSI in line with this agreement is to deliver Products
        just in time and on a zero defect basis. The rate to which the parties
        agree that supply performance is adequate should be:

        On quality                 98% (based on shipment rejects)
        On delivery                99% (with a deviation of five days)

9.3.    Teknika holds the right to inspect, by means of an expert appointed by
        itself, at any time, with 30 days previous notice, and at least once a
        year, the manufacture and quality control procedures by LSI with respect
        to the Product. LSI retains the right to have Teknika and any inspector,
        whether a Teknika employee or not, sign a binding confidentiality
        agreement against disclosure to third parties of LSI confidential
        information.

9.4.    LSI is currently in the process of reviewing its Quality Assurance
        program against the ISO rules and will update its system accordingly.

        In accordance with Teknika's guidelines and based on ISO 9001, LSI will
        fulfill all actions necessary to meet Teknika's quality system
        requirements and address corrective actions to noncompliance items as
        specified in Teknika's QS audit reports.

Art. 10. Packaging

Unless the packaging is pre-described in the Teknika pack-specification of the
Products (Appendix I), LSI must take care of the packaging of the Products in
such a way that the Products will not be damaged during normal transport
conditions.

Art. 11. Continuity of Supply

11.1.   LSI and Teknika are aware that the continuity of supply of the Products
        is essential to Teknika's business.

        LSI will inform Teknika as soon as possible, but at least with twelve
        (12) months prior written notice, of any planned intent to discontinue
        the manufacture and/or supply of the Products, and as soon as possible
        of any potential or real inability to manufacture and/or supply the
        Products.

5
<PAGE>   6

11.2.   In order to secure the continuous supply of the Products, LSI and
        Teknika have agreed to the following:

        (i) LSI has set up a contingency plan as attached as Appendix III. (the
        "Contingency Plan") for the uninterrupted supply of the Products to
        Teknika. LSI is an associate member of the Biotechnology Development
        Institute (BDI) of the University of Florida and such membership affords
        LSI access to an alternative location for the production of the Products
        at the BDI laboratory facility for a period of up to six months. LSI and
        the University of Florida have entered into an agreement for these
        purposes (the "University Agreement").

        LSI hereby agrees to undertake all possible and necessary preparations,
        including storage of a limited quantity of the Products together with a
        substantial quantity of production substrates and long lead time
        supplies at the BDI facility, in order to be prepared for immediate
        implementation of the Contingency Plan.

        (ii) In addition to the University Agreement, LSI has entered into
        understandings with various hatcheries for the supply of day old W36
        chickens which are used in the manufacture of the Products (the "W36
        Agreement"). Where LSI is not willing to supply the Products or is not
        able to supply the Products for more than two (2) Purchase Periods, at
        the option of Teknika, LSI will immediately assign all its rights under
        the University Agreement, the W36 Agreement and any other agreements
        essential to the manufacture of the Products to Teknika.

        (iii) Teknika is hereby granted a stand-by right to direct the operation
        of LSI's enzyme production facilities and all appropriate personnel at
        LSI's enzyme production facilities as provided in the Facilities
        Operation Agreement attached as Appendix III.A. In the event of a
        "Triggering Event" as defined in the Facilities Operation Agreement, the
        parties, shall enter into that agreement to provide Teknika the right to
        direct the use of the premises and employ the personnel at the premises
        to the extent needed for the continued supply of the Products.

        (iv) In addition to Appendix III.A. Teknika is hereby granted a stand by
        option to obtain a non exclusive licence from LSI for its NASBA enzyme
        production technology (the "License Agreement") in the form as attached
        as Appendix III.B. This option may only be exercised by Teknika where
        LSI is not willing or not able to supply the Products for more than two
        (2) Purchase Periods. The License Agreement will include (i) a right to
        one sub license for the manufacture of the Products, (ii) an obligation
        of confidentiality on both Teknika and its sub licensee, and (iii) a
        provision that the License Agreement will terminate within six (6)
        months after LSI has resumed the supply of the Products as provided for
        in this Agreement, taking into consideration a smooth continuation of
        supply in commercial quantities as communicated by Teknika's forecasting
        system.

        For these purposes LSI will provide Teknika will all necessary know how,

6
<PAGE>   7
         information, documents and licenses to enable Teknika to make or have
         made the Products, including but not limited to the following
         information: relevant production and manufacturing process' and
         procedures' protocols in accordance with LSI's own internal GMP control
         system, list of used raw materials and relevant suppliers, relevant
         Quality Control Manuals and most recent production history file (the
         Know How). The Know How will be held in escrow by a third party to be
         appointed by LSI and Teknika jointly.

         Parties agree that this paragraph does not release the parties from
         their contractual obligations or set aside the rights they have under
         this Agreement including but not limited to the rights of the parties
         under paragraph 12.2.

11.3.    At the request of Teknika, LSI shall provide Teknika, at Teknika's
         cost, with the necessary training to apply the information and Know
         How to enable Teknika to properly exercise its rights under this
         article. Teknika is willing to pay all reasonable travel and
         accommodation expenses incurred by LSI in sending its personnel to
         Teknika for the above mentioned training.

Art. 12. Duration and termination

12.1.    This Agreement shall become effective on the Effective Date and shall
         continue to be in force until January 1st, 2003. Thereafter, it will
         be automatically extended for subsequent periods of 2 years, unless 12
         months prior to the initial period, or the expiration date of such
         renewed period, notice of termination is given by one party hereto to
         the other by registered mail.

12.2.    Notwithstanding the preceding paragraph, this Agreement may be
         terminated forthwith by notice given by registered mail:

         a.  by either party in the event the other party shall breach any of
             its obligations under this Agreement and shall fail to remedy such
             breach within sixty (60) days from receipt of notice of such breach
             by the party not in default; or

         b.  by either party in the event of the other party's liquidation,
             bankruptcy or state of insolvency; or

         c.  by either party in the event of an assignment of this Agreement by
             the other party to a third party without the non-assigning party's
             written approval; or

         d.  by either party in the event of change in control of the other
             party or a transfer of all or a substantial part of the other
             party's business.

12.3.    In case of termination of this Agreement, Teknika will have the right
         to sell out its stock, existing at the moment of termination.

7
<PAGE>   8
Art. 13. Force Majeure

Neither party shall be liable or in breach of any provision of this Agreement
for any failure or delay on its part to perform any obligation hereof because
of force majeure (such as, but without limitation, strikes, unforeseeable
lockouts, shortage of raw materials or energy, any governmental regulations or
Acts of God) provided that such party shall promptly give notice to the other
party of such occurrence and shall do all things reasonable to eliminate the
effect thereof to the extent possible.

Art. 14. Indemnification

Teknika and LSI agree to indemnify and hold the other party harmless against
any claims, damages, liabilities and costs arising out of a breach by Teknika or
LSI of any of their respective obligations under this Agreement.

Art. 15. Dispute Resolution

15.1.    The parties shall attempt in good faith to resolve promptly any
         dispute, arising out of or relating to this Agreement by negotiation.
         If despite such negotiations the matter cannot be resolved amicably,
         the parties shall endeavor to settle any dispute, other than a patent
         dispute, by non-binding mediation under the then current Center for
         Public Resources Procedures for Mediation of Business Disputes in
         Europe (CPR).

         Unless otherwise agreed, the parties agree to select the mediator from
         one of the CPR Panels of Distinguished Neutrals within 30 days of a
         written request of any party to the other to start a mediation and, if
         no such Neutral has been agreed upon within the 30 day's period, each
         party may notify CPR to initiate a selection process. The seat of
         mediation shall be The Hague, The Netherlands, or any other location
         mutually agreed upon by parties.

15.2.    If the dispute has not been resolved by non-binding means as provided
         in paragraph 15.1. hereof within 60 days (or an agreed extended period)
         of acceptance by the mediator of his appointment, or if one of the
         parties has informed the other party in writing that it is not willing
         to start or proceed with the mediation as contemplated in paragraph
         15.1., the dispute shall be exclusively settled by a Court of competent
         jurisdiction within The Hague, The Netherlands.

Art. 16. Entire Agreement

This Agreement sets forth the entire agreement between the parties hereto
relating to the subject matter of this Agreement, and supersedes all prior
agreements. This Agreement may be modified in writing only.

8
<PAGE>   9
Art. 17. Severability clause

The invalidity or impracticability of any terms of this Agreement shall not
affect the validity of its remaining terms. In such a case, the parties shall
agree without delay on a valid substitute term which shall approximate as
closely as possible the purpose of the invalid or impracticable term.

Art. 18. Miscellaneous

This Agreement shall be personal to the parties and may not be assigned, except
by mutual consent of the parties, not to be unreasonably withheld, other than
to a successor to or assignee of all or substantially all of that part of the
business of the assigning party to which to Product relates. The individuals
who have executed this Agreement warrant that they have done so with full
authority to execute such documents on behalf of their corporations and shall,
upon demand, present documents verifying that authority.

Art. 19. Confidentiality

19.1.    Both Teknika and LSI possess confidential and proprietary information
         and data concerning Enzymes and Nucleotides for Nasba reactions,
         stabilization processes and Teknika's Q.C. procedures for Nasba
         reagents. Both Teknika and LSI wish to exchange their Confidential
         Information, as hereinafter defined, in order to support this Agreement
         concerning the supply of Enzyme Cocktails, subject to the terms and
         conditions of this Article 19.

19.2.    "Confidential Information" shall mean all information disclosed by one
         party to the other in written form and clearly marked 'confidential'
         or, if communicated verbally, confirmed in writing within fifteen (15)
         days after verbal communication and clearly marked 'confidential'.

19.3.    Upon the execution of this Agreement, each party shall supply the other
         party with such Confidential Information as deemed appropriate by LSI
         and Teknika respectively.

19.4.    Unless provided otherwise in this Agreement, the disclosure of
         Confidential Information shall not or may not be construed as granting
         the other party any right or licence to the Confidential Information
         for any use other or further than the requirements of this Supply
         Agreement.

19.5.    Each party agrees that it will not use any part of the Confidential
         Information supplied by the other party except as required by this
         Supply Agreement and that it will keep, both during the evaluation
         period and thereafter, said Confidential Information secret and
         confidential, and that it shall not disclose any of it to any third
         party except to the extent necessary to support this Supply Agreement
         and under the same secrecy obligation as herein

9

<PAGE>   10
         contained. The provisions of this paragraph shall, however, not apply
         to any part of such Confidential Information which:

         a.  is at present publicly known or hereafter becomes publicly known
             through no fault of the receiving party, or its employees; or

         b.  was already known to the receiving party on the date of disclosure
             by the other party, provided that such prior knowledge can be
             adequately substantiated by documentation; or

         c.  properly and lawfully becomes available to the receiving party from
             other sources; or

         d.  is independently developed by the receiving party or its affiliates
             without the benefit of any disclosure by the disclosing party.

         Documents and important papers and/or forms, etc. will be returned to
         the party from which they originate immediately after expiration of
         this Agreement.

19.6.    This obligation of confidentiality will also apply to mutual
         developed information.

Art. 20. Appendices

All appendices (including all exhibits) to this Agreement constitute an
integral part of the Agreement.

Art. 21. Notices

Any notice required under this Agreement shall be made in writing by registered
mail to the Parties at their respective addresses first above written or as
subsequently changed by notice duly given.

Art. 22. Applicable Law

The laws of The Netherlands govern this Agreement. English should be the
official language of this Agreement.

10
<PAGE>   11
In witness whereof, the parties hereto have caused this Agreement to be executed
in duplicate by their respective duly authorized officers the day and year first
above written.

For and on behalf of                              For and on behalf of
ORGANON TEKNIKA B.V.                              LIFE SCIENCES, INC.
Boxtel                                            St. Petersburg

/s/ C.H.J. van Kollenburg                         /s/ Alex A. Burns
-------------------------                         -----------------
By: C.H.J. van Kollenburg                         By: Alex A. Burns
Title: Manager International Purchasing           Title: Vice President

/s/ Drs. R.J. Wolters
-------------------------                         ----------------
By: Drs. R.J. Wolters                             By:
Title: Manager International Manufacturing        Title:
e:

11
<PAGE>   12

                                   APPENDIX I

                             PRODUCT SPECIFICATIONS

                                 (NOT INCLUDED)

<PAGE>   13

                                  APPENDIX II

                                  PRICING DATA

                                 (NOT INCLUDED)

<PAGE>   14

                                  APPENDIX III

Contigency Plan.

14
<PAGE>   15

LIFE SCIENCES INC. LOGO

                               LIFE SCIENCES INC.
                       ENZYME PRODUCTION CONTINGENCY PLAN

BASIS FOR THE PLAN:

Life Sciences is a producer of nucleic acid modifying enzymes used in
proprietary, commercial tests for diagnosis of human disease and the
identification of environmental pathogens. Because Life Sciences may be the sole
source of these enzyme for certain final product manufacturers, including
itself, and the enzymes together with the tests kits containing them have a
defined and limited shelf life, the company has established this plan to enable
sustained temporary production of certain of its enzyme products in the event
the company suffers catastrophic loss of its production facilities.

While some of the company's enzyme products are of bacterial origin, production
of its avian myeloblastosis virus (AMV) reverse transcriptase (RT) product
requires the use of day-old W36 chickens as a host for production of the viral
substrate that is the source of the enzyme. Because the W36 chicken is not a
universally available species and the infrastructure necessary for the
production of the virus is a space intensive and skillfully crafted one, this
plan is substantially reliant on the use of cryogenically preserved production
intermediates to assure continuous production of all the enzyme products.

Expedited start up of production of viral substrate would present substantial
logistic and financial challenges.

NATURE OF THE RISK:

The Company's facilities in St. Petersburg, Florida are situated approximately
3 miles east of the Gulf of Mexico and nearly equidistant westward from Tampa
Bay. The Gulf and its bays and coves are known paths for hurricanes of varying
strengths. Because buildings constructed as Life Sciences' facilities have been
demolished by the water and winds attendant to category 4 and higher hurricanes,
the company is at risk for loss of its facilities. From time to time the Tampa
Bay region also experiences tornadoes and other cyclonic wind phenomena that
possess sufficient destructive forces to destroy Life Sciences' enzyme
production facilities.

Because tornadoes and particularly hurricanes typically cause substantial
localized and even region-wide damage to structures, the post-event rebuilding
of region-wide wind related damage is subjected to the competitive bidding for
the available construction materials and human resources, Life Sciences can
make no representations as to a potential timetable for rebuilding of its
facilities following wind related natural disasters. As such, this contingency
plan focuses on external, out-of-region facilities for production of its
critical enzyme products.

    P.O. Box 48039, St. Petersburg, Florida 33743 - 2900 72nd Street North,
                         St. Petersburg, Florida 33710
              Telephone (727) 345-9371 - Facsimile (727) 347-2957
                     email: lsi1@gte.net - www.lifesci.com
<PAGE>   16

Life Sciences Inc.                            Enzyme Production Contingency Plan
Page 2

THE PLAN:

REBUILDING MANUFACTURING CAPABILITY:  Life Sciences maintains almost $2 million
of insurance coverage for catastrophic damage to its buildings and production
machinery together with and coverage for up to $300,000 in lost revenues. The
company believes these amounts are sufficient to fund the restart of its enzyme
production in leased or rebuilt facilities, located within reasonable access of
its existing cadre of employees, within 3 months following even total
destruction of its existing laboratories.

INTERIM PRODUCTION:  Life Sciences has entered into an agreement with an arm of
the University of Florida for at-will utilization of laboratory space and
"common-use" assets at the Sid Martin Biotechnology Development Institute
located in Alachua, Florida. The Institute was founded as a Biotechnology
Incubator to support the development of small businesses created primarily to
commercialize biotechnology related innovations which are originated by the
faculty and staff of the University of Florida.

The University of Florida is one of the leading research universities of the
United States. Situated approximately 150 miles northeast of St. Petersburg,
the University has a population of over 43,000 graduate and undergraduate
students and over 5000 faculty and professional staff. With over $300 million
in annual government and industry funding for its research programs in various
disciplines, the University is world renowned for its innovations in medicine
and agricultural sciences. Since contemporary developments in both of these
fields is almost inextricably linked with molecular biology, the concept of a
biotechnology incubator with the resources described in the accompanying
brochure is not without precedent.

Life Sciences' agreement with the Institute specifically permits the company to
locate its own cryogenic storage cabinet in Rm. 154 of the Institute for
extended term storage of as much as 1 kilogram of pelletized, frozen avian
myeloblastosis virus and various fermentation products. The storage cabinet will
be fitted with a recording thermometer and back-up liquid or gaseous nitrogen or
carbon dioxide system to accommodate at least 24 hours of at-set point operation
in the event of critical component failure or loss of electrical power. The
cabinet also will be equipped with audible local alarm and remote signaling for
annunciation of sustained excursions of cabinet temperature in >=5 (degree) C
in excess of the set point and higher.

The current 1 year demand by Akzo Nobel for the AMV RT component of the Nasba
enzyme mix AMV reverse transcriptase can be satisfied from 300 grams of
pelleted avian myeloblastosis virus and 80 grams of E. coli, for recovery of
cloned T7RNA polymerase and 200 grams of a second E. coli host for recovery of
cloned RNase H; Life Sciences will maintain sufficient back-up substrates to
support 6 months of AN's annual requirement at its Alachua, Florida based
storage site.

                               LIFE SCIENCES INC.
  P.O. Box 48039, St. Petersburg, Florida 33743 - 2900 72nd Street North, St.
                           Petersburg, Florida 33710
              Telephone (727) 345-9371 - Facsimile (727) 347-2957
                     email: 1si1@gte.net - www.lifesci.com
<PAGE>   17
Life Sciences Inc.                            Enzyme Production Contingency Plan
Page 3

While the RT enzyme activity in cryogenically stored AMV exhibits a half-life in
excess of 7 years, the Company's limited experience with pelletized E.coli
stored at such temperatures confirm a high life of associated enzyme activities
of 6 months. For this reason the inventory of pelletized E.coli will be
turned-over on a semi annual basis, while the stored AMV will be exchanged on a
2 year basis.

The Agreement also provides for the Company's use of laboratory facilities with
the characteristics outlined below for 7-10 continuous days per month, for not
fewer than 4 months.

         Use of laboratory facilities which would provide  1) sufficient work
         space for two technicians, 2) a source of 200 L/day of high purity
         water (resistivity >= 18 meg ohm, pyrogen free), 3) twenty five (25)
         linear feet of lab counter space, and 4) ready access to a walk-in cold
         room for protein purification.

         In addition to the use of BDI common use equipment, we will install the
         following apparatus on an interim basis:

                  FPLC apparatus (Pharmacia AKTA or equivalent)
                  Fraction collector
                  Freezer -20(degree)C (NOT frost free)
                  Heated water bath
                  Scintillation counter
                  Shaker, reciprocal
                  Isotope [3H] work area

The Agreement further provides that Life Sciences will be able to acquire and
install critical capital items for its sole use in production of enzymes in Rm.
154 of the Institute.

The schedule of Sid Martin Institute common use equipment is appended as
Appendix 1, and the Institute's floor plan is labeled Appendix 2.

                               LIFE SCIENCES INC.
  P.O. Box 48039, St. Petersburg, Florida 33743 - 2900 72nd Street North,
                         St. Petersburg, Florida 33710
              Telephone (727) 345-9371 - Facsimile (727) 347-2957
                     email: lsi1@gte.net - www.lifesci.com
<PAGE>   18
                               LIFE SCIENCES, INC

          Equipment to be Acquired for Contingent Production Facility
                      Biotechnology Development Institute

                                Alachua, Florida

<TABLE>
<CAPTION>
EQUIPMENT                                                                                MODEL/VENDOR
---------                                                                                ------------
<S>                                                                                 <C>
chromatography columns; 5.0 x 60 cm, 2.5 x 120 cm, 2.0 x 100 cm                     SpectraChrom LC Column
chromotography column, 2.5 X 61 cm                                                  SpectraChrom LC Column
chromotography column, 1.5 X 10 cm                                                  SpectraChrom LC Column
chromotography column, 2.5 X 130 cm                                                 SpectraChrom LC Column
chromotography column                                                               Pharmacia XK50
chromotography column                                                               Pharmacia Index 70/500
chromotography column                                                               Pharmacia Index 70/950
chromotography column                                                               Pharmacia Index 100/500
conductivity meter                                                                  Orion 180 VWR
digital balance                                                                     AND EP-60KA
                                                                                    Cole Parmer
egg incubator                                                                       Petersine S6I
egg hatchbator                                                                      Petersine S6H
FPLC apparatus                                                                      Pharmacia 18-1128-41
fraction collector                                                                  Specta Chrom CF-1
gradient mixer                                                                      Pharmacia GM-1
heat lamp
pipettor, automatic                                                                 DrummondPipetAid VWR
pipertors x 3                                                                       Rainin R20, R200, R1000
poultry brooder cages with water/feed trays and heaters, 50ea                       MPI Poultry Brooders
poultry brooder cages with water/feed trays w/o heaters, 50ea                       MPI Poultry Brooders
refractometer                                                                       Bausch and Lomb VWR
syringe, glass inoculating x 2                                                      VWR BD2004
</TABLE>
<PAGE>   19

ICBR CORE LABORATORY FACILITIES

DNA Synthesis       Hybridoma Lab            Molecular Biomarkers
DNA Sequencing      Flow Cytometry           Immunological Analyses
Protein Chemistry   Histology                Genetic Analysis
Protein Expression  Electron Microscopy      Reproductive Analysis
Glycobiology        Biological Computing     Education and Training

B.I.G. AND NETWORKING

Licensees automatically become members of the Biotechnology Industry Group
(BIG), an organization created to help biotechnology businesses network and
leverage opportunities for making biotechnology a voice in Florida and in the
entire southeast. Networking is an important, but often overlooked feature of
incubators that add higher value to companies!

UNIVERSITY AFFILIATION

All licensees can receive UF courtesy affiliation status, entitling them to a
UFID all-in-one card. This ID provides access to campus libraries, recreation
and entertainment facilities, parking, and other UF facilities.

For a copy of the "Guidelines for the Qualification and Selection of Licensees
for the Incubator Program at the BDI Building," please call (904) 462-0880 or
462-0876.

<PAGE>   20
                           THE BIOTECHNOLOGY PROGRAM

                             UNIVERSITY OF FLORIDA

                              COMPANIES AT THE BDI

AQUAGENE, INC.: AquaGene, Inc. is a biotechnology company that will produce
modified proteins and peptides using transgenic fish. The technology is being
developed to express in large quantities, high quality post translationally
modified proteins in very high yield using transgenic fish as the production
vehicle. Fish provide numerous economic and technical advantages for the
production of the many modified proteins that are already in use, or that will
be needed as biopharmaceuticals of the future. AquaGene is developing the
transgenic fish production technology, as well as unique overexpression and
analysis capabilities, and has relations established for the production of
biopharmaceuticals under cGMP conditions. Contact: John Rogers, president, (904)
418-1400, johnro@biotech.ufl.org.

CURAGEN CORP.: CuraGen Corp. is the acknowledged leader in genomics research as
well as the development of the technology used in genomics research. It has
already received three Advanced Technology Awards from the Department of
Commerce, joining the ranks of the few companies such as IBM, AT&T and 3M who
have achieved this distinction. CuraGen has a division in Alachua, in
collaboration with the University of Florida. This division focuses on the
identification and discovery of human disease genes and agriculturally relevant
plant genes, using a positional cloning approach. Contact: Dr. Steven Colman,
Operations Mgr., (904) 462-0870, scolman@biotech.ufl.org.

ERAGEN BIOSCIENCES, INC.: EraGen Biosciences, Inc. was founded by Dr. J. David
Rozzell and Professor Steven A. Benner, who has come to the University of
Florida from the Swiss Federal Institute of Technology. EraGen has exclusive
licenses to five core patents and patent applications concerned with the
structure and behavior of proteins, nucleic acids, and nucleic acid analogs.
Sulfonics is developing its technology to generate products/services in four
areas: 1) Sulfur-linked oligomeric libraries (SOL), a proprietary class of
building blocks for constructing bioavailable combinatorial libraries and
antisense compounds; 2) A software package that implements Evolution-based
Structure Prediction (ESP) for predicting the three dimensional structure of
proteins from amino-acid sequence; 3) An Expanded Genetic Information System
(AEGIS) composed of non-standard bases, which combines the molecular recognition
characteristics of the bases found in DNA and RNA with broadened chemical
functionality and molecular diversity and 4) Expanded Combinatorial Selection
(EXCSEL) for the creation of new ligands, receptors, and catalysts, using
non-standard bases through invitro evolution. Applications for commercialization
of EraGen's technology will be advanced in the areas of drug discovery and novel
diagnostic products through a business blend of proprietary research projects
and collaborative research and licensing agreements with the pharmaceutical and
biotechnology industry. Contact: Gideon Shapiro, Dir. of Research, (904)
462-2000, gshapiro@biotech.ufl.org.

EQUITECH LABORATORIES, INC.: This company was started by Dr. Daniel C. Sharp,
from the University of Florida, and concentrates on products and services
dealing with reproductive physiology and efficiency in the horse and livestock
industries. Initial research focuses on improving reproductive capacity during
the first three weeks of pregnancy, thus enhancing uterine development, and
improving embryonic growth. Dr. Sharp's technology will be of keen interest to
horse breeders and the industry, since equine embryonic losses are estimated to
be as high as 25% in the first three weeks of pregnancy. Equitech also offers
endocrine diagnostic capabilities to veterinarians throughout Florida and the
United States. In the future, Dr. Sharp hopes to develop "barnside" endocrine
diagnostic tests that can render clinical diagnostic information to the
veterinarian, livestock manager, or companion animal owner on site. Equitech
estimates that one million mares could benefit from its product. Successful
development of its products means that the benefits of Equitech's technology
could be extended to the entire livestock and companion animal markets.
Contact: Dr. Daniel Sharp, President, (904) 418-1525, equitech@biotech.ufl.org.

GEMINI HEALTH TECHNOLOGIES, INC.: Gemini Health Technologies, Inc. is
developing commercial applications based on its proprietary technologies in two
distinct areas: (1) non-invasive drug delivery technologies to improve the
administration of therapeutics to diseased tissue; and (2) drug design
technologies to create new therapeutic agents aimed at the genes and proteins
being discovered by scientists as the underlying causes of complex diseases.
The disease areas of initial focus are cancer, inflammation and chronic tissue
damage. Drug delivery is an emerging market of over $12 billion in sales and is
growing at a rate in excess of 20% per annum. The company recently signed an
agreement with Elan Corp., plc., a world leader in the drug delivery field.
Gemini is combining the two companies' technologies to improve the
administration of topical drugs for indications such as skin cancer and
psoriasis. The drug design programs are conducted in-house or in collaboration
with scientists at the University of Florida and elsewhere and often utilize
the company's expanding library of proprietary drugs including its anti-cancer
nucleobases. Contact: Dr. Arup Sen, President, Chairman & CEO, (904) 462-2249,
arupsen@aol.com.

        [Interdisciplinary Center for Biotechnology Research Letterhead]
<PAGE>   21
                                   APPENDIX 1

                            BDI COMMON USE EQUIPMENT

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------
Description                                 Manufacturer             Location     Status        Contact
------------------------------------------------------------------------------------------------------------
<S>                                         <C>                      <C>          <C>          <C>
OVEN, MODEL 130 MECH 120V                    Precision                  116A      Common
------------------------------------------------------------------------------------------------------------
P5-200 COMPUTER                              Micron                     106       Library      Brian Almira
------------------------------------------------------------------------------------------------------------
P5-200 COMPUTER                              Gateway 2000               106       Library      Brian Almira
------------------------------------------------------------------------------------------------------------
COPIER W/STAPLER                             Xerox                      101       Common
------------------------------------------------------------------------------------------------------------
FAX MACHINE                                  Toshiba                    101       Common
------------------------------------------------------------------------------------------------------------
WHEEL WRITER                                 IBM                        106       Library
------------------------------------------------------------------------------------------------------------
CAMERA, NIKON N6006 W/LENS & TRIPOD          Nikon                      159       Common       Jim Gilbreath
------------------------------------------------------------------------------------------------------------
COMPUTER, POWERMAC 8500/120 W/17" MONIT      Apple                      106       Library
------------------------------------------------------------------------------------------------------------
SCANNER UMAX POWERLOOK II                    Umax                       106       Library
------------------------------------------------------------------------------------------------------------
PRINTER, LASERWRITER 60/600 PS               APPLE                      106       Library
------------------------------------------------------------------------------------------------------------
PRINTER, COLOR LASERJET                      HP                         106       Library
------------------------------------------------------------------------------------------------------------
CAMERA -- VIDEO DEI-470                      Optronics Engineering      154       Common       Morphogenesis
------------------------------------------------------------------------------------------------------------
FREEZER, GLASS FRONT                         Puffer Hubbard             167       Common
------------------------------------------------------------------------------------------------------------
FREEZER -- 80                                Revco                      169       Common
------------------------------------------------------------------------------------------------------------
FREEZER, UPRIGHT ULTRA LOW TEMPERAT          Forma Scientific           169       Common
------------------------------------------------------------------------------------------------------------
FREEZER, UPRIGHT ULTRA LOW TEMPERAT          Forma Scientific           169       Common
------------------------------------------------------------------------------------------------------------
</TABLE>

LIFE SCIENCES INC.

ENZYME PRODUCTION CONTINGENCY PLAN                                           A-1
<PAGE>   22

                            BDI COMMON USE EQUIPMENT

<TABLE>
<S>                                                   <C>                        <C>               <C>               <C>
------------------------------------------------------------------------------------------------------------------------------------
INCUBATOR COMPACT-CO2                                 Thermdyne                  156               Common            UAT
------------------------------------------------------------------------------------------------------------------------------------
MICROSCOPE FLUORESCENCE                               Olympus                    154               Common            Morphogenesis
 IMT-2
------------------------------------------------------------------------------------------------------------------------------------
MONITOR (Fluor Micro)                                 Sony                       154               Common            Morphogenesis
------------------------------------------------------------------------------------------------------------------------------------
REFRIGERATOR                                          Magic Chef                 167               Common
------------------------------------------------------------------------------------------------------------------------------------
AUTOCLAVE, SMALL                                      Consolidated Stills &      139               Common
                                                      Sterilizers
------------------------------------------------------------------------------------------------------------------------------------
BALANCE TOP LOADING                                   Ohaus                      147               Common
------------------------------------------------------------------------------------------------------------------------------------
CAMERA-16MM                                           Bolex                      147               Common
------------------------------------------------------------------------------------------------------------------------------------
CENTRIFUGE, OPTIMA LE-80                              Beckman                    147               Common
------------------------------------------------------------------------------------------------------------------------------------
CENTRIFUGE, MICRO-FLOOR                               Beckman                    147               Common
 MODEL
------------------------------------------------------------------------------------------------------------------------------------
DIGITAL IMAGING SYSTEM                                Alpha Innotech-            147               Common
------------------------------------------------------------------------------------------------------------------------------------
FREEZE DRYING SYSTEM, BULK                            Genesis                    147               Common
 VIRTIS
------------------------------------------------------------------------------------------------------------------------------------
HPLC SYSTEM-TITANIUM                                  Biorad                     147               Common
------------------------------------------------------------------------------------------------------------------------------------
ICE MACHINE                                           Welbilt Comp.              147               Common
------------------------------------------------------------------------------------------------------------------------------------
MICROSCOPE                                            Micromaster                147               Common
------------------------------------------------------------------------------------------------------------------------------------
MICROSCOPE, B MAX BX-50                               Olympus                    147               Common
 W/ACCESS
------------------------------------------------------------------------------------------------------------------------------------
MICROSCOPE, INVERTED                                  Datco Inc.                 147               Common
------------------------------------------------------------------------------------------------------------------------------------
PRINTER, DOT MATRIX                                   Tandy                      147               Common
------------------------------------------------------------------------------------------------------------------------------------
PUMP, MICROPEREX PERISTALTIC                          Bromma                     147               Common
------------------------------------------------------------------------------------------------------------------------------------
SIPPER, TYPE L 204-08270-01                           Shimadzu Corp.             147               Common
------------------------------------------------------------------------------------------------------------------------------------
SPECTOPHOTOMETER                                      Hitachi                    147               Common
------------------------------------------------------------------------------------------------------------------------------------
SPECTOPHOTOMETER-RECORDING                            Shimadzu Corp.             147               Common
------------------------------------------------------------------------------------------------------------------------------------
SPECTOPHOTOMETER-DU SERIES                            Beckman                    147               Common
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

LIFE SCIENCES INC.

ENZYME PRODUCTION CONTINGENCY PLAN                                           A-2
<PAGE>   23

                            BDI COMMON USE EQUIPMENT

<TABLE>
<S>                                  <C>                      <C>        <C>             <C>
------------------------------------------------------------------------------------------------------
THERMOCYLER, UNO W/BLOCK &           Biotron                  147        Common
 HEATED (2)
------------------------------------------------------------------------------------------------------
PH METTER, ACCUMET 910               Fisher Scientific        149        Fermenter       Jim Gilbreath
------------------------------------------------------------------------------------------------------
BALANCE, ELECTRONIC PC440            Mettler-                 149        Fermenter       Jim Gilbreath
------------------------------------------------------------------------------------------------------
CENTRIFUGE, MODEL Z41                New Brunswick            149        Fermenter       Jim Gilbreath
------------------------------------------------------------------------------------------------------
COMPUTER, P5-75 PENT CD W/15"        Gateway                  149        Fermenter       Jim Gilbreath
 MONIT
------------------------------------------------------------------------------------------------------
FERMENTOR, BIOFLO 3000 SLANT         New Brunswick            149        Fermenter       Jim Gilbreath
 RACK
------------------------------------------------------------------------------------------------------
FERMENTOR, BIOFLO 5000               New Brunswick            149        Fermenter       Jim Gilbreath
 W/EXHAUST CO
------------------------------------------------------------------------------------------------------
HOMOGENIZER, HIGH PRESSURE           Niro Soavi               149        Fermenter       Jim Gilbreath
------------------------------------------------------------------------------------------------------
SHAKER, INNOVA 4230                  New Brunswick            149        Fermenter       Jim Gilbreath
 W/PLATFORM
------------------------------------------------------------------------------------------------------
SHAKER, INNOVA 4330                  New Brunswick            149        Fermenter       Jim Gilbreath
 W/PLATFORM
------------------------------------------------------------------------------------------------------
WATER CIRCULATING SYSTEM,            Haskris                  149        Fermenter       Jim Gilbreath
 REFRIGERA
------------------------------------------------------------------------------------------------------
CENTRIFUGE REFRIGERATED (rotor)      Beckman                  167         Common
------------------------------------------------------------------------------------------------------
CENTRIFUGE REFRIGERATED              Beckman                  167         Common
 TABLE TOP
------------------------------------------------------------------------------------------------------
INCUBATOR-CO2                        Fisher Scientific         ?          Common
------------------------------------------------------------------------------------------------------
OSMOMETER, VAPRO                     Vapro                    174         Common         Predation
------------------------------------------------------------------------------------------------------
REFRIGERATOR-GLASS DOOR              Puffer Hubbard           155         Morphogenesis  Morphogenesis
------------------------------------------------------------------------------------------------------
CALIBRATION CELL                     Transdyne General        149         Common
------------------------------------------------------------------------------------------------------
CENTRIFUGE-CYTOPRO,                  Wescor                   167         Common
 W/ACCESSORIES
------------------------------------------------------------------------------------------------------
MICROBETA PLUS, W/CELL               Wallac                   167         Common
------------------------------------------------------------------------------------------------------
</TABLE>

LIFE SCIENCES INC.

ENZYME PRODUCTION CONTINGENCY PLAN                                           A-3
<PAGE>   24
                            BDI COMMON USE EQUIPMENT

<TABLE>
---------------------------------------------------------------------------------------
<S>                             <C>                   <C>      <C>        <C>
HARVESTER
---------------------------------------------------------------------------------------
MICROPLATE EIA READER           Biotek Instrument     167      Common
---------------------------------------------------------------------------------------
MICROPROCESS 202C (Frac)        Gilson                167      Common
---------------------------------------------------------------------------------------
MICROSCOPE, CK-2                Olympus               168      Ixion      Ixion
---------------------------------------------------------------------------------------
AUTOCLAVE-TABLE TOP             Pelton & Crane        169      Common
---------------------------------------------------------------------------------------
BALANCE ANAYTICAL #AE240        Mettler-              169      Common
---------------------------------------------------------------------------------------
CENTRIFUFGE-CYTO                Inter. Equip.         169      Common
---------------------------------------------------------------------------------------
CENTRIFUGE                      International         169      Common
                                Equipment
---------------------------------------------------------------------------------------
CENTRIFUGE-ULTRA, OPTIMA LE-    Beckman               169      Common
 80
---------------------------------------------------------------------------------------
CENTRIFUGE-TABLE-TOP            Inter. Equip.         169      Common
---------------------------------------------------------------------------------------
CENTRIFUGE, REFRIGERATED        Beckman               169      Common
---------------------------------------------------------------------------------------
CONCENTRATOR                    Savant                169      Common
---------------------------------------------------------------------------------------
DARKROOM/Film Developer         Consolidated          169      Common
                                International
---------------------------------------------------------------------------------------
EVAPORATOR ASSEMBLY, MDL        Savant                169      Common
 12115
---------------------------------------------------------------------------------------
INCUBATOR ISOTEMP               Fisher Scientific     169      Common
---------------------------------------------------------------------------------------
INCUBATOR SHAKER/TRAY           Queue Orbital         169      Common
 MODEL 4730
---------------------------------------------------------------------------------------
INCUBATOR, DRY                  Blue M                169      Common
---------------------------------------------------------------------------------------
INCUBATOR, MDL G24 SHAKER       New Brunswick         169      Common
---------------------------------------------------------------------------------------
OVEN, HYBRIDIZATION             Stovall               170      Common     Ixion
---------------------------------------------------------------------------------------
OVEN, MDL 130 MECH              Precision             169      Common
---------------------------------------------------------------------------------------
PH MODEL 340 METER              Corning Inc.-NY       169      Common
---------------------------------------------------------------------------------------
PRESSURE BLOTTER                Posiblot              169      Common
---------------------------------------------------------------------------------------
</TABLE>

LIFE SCIENCES INC.

ENZYME PRODUCTION CONTINGENCY PLAN                                          A-4

<PAGE>   25
                            BDI COMMON USE EQUIPMENT

<TABLE>
--------------------------------------------------------------------------------------------------------
<S>                                <C>                         <C>        <C>           <C>
PRINTER, VIDEO                     Sony                        169        Common
--------------------------------------------------------------------------------------------------------
ROTOR W/SHIELD AND DOME            International               169        Common
                                   Equipment Comp.
--------------------------------------------------------------------------------------------------------
ROTOR, HORIZONTAL                  International               169        Common
                                   Equipment Comp.
--------------------------------------------------------------------------------------------------------
SAFETY CABINET-CHEMICAL            Fisher Scientific           169        Common
--------------------------------------------------------------------------------------------------------
SHAKER BATH #15-                   Blue M                      169        Common
--------------------------------------------------------------------------------------------------------
SLAB CELL-GEL                      Bio Rad                     169        Common
--------------------------------------------------------------------------------------------------------
VACUUM BLOTTER SYSTEM              Biorad                      169        Common
--------------------------------------------------------------------------------------------------------
WATER BATH NAPCO 220A              Napco Scientific Co.-       169        Common
                                   Org.
--------------------------------------------------------------------------------------------------------
ANIMAL CABINET, POSITIVE           FluFrance-                  SPF        Ixion         Ixion
 PRESSURE
--------------------------------------------------------------------------------------------------------
AUTOCLAVE, REIMERS RH-80,          Consolidated Stills &       175        Common
 LARGE                             Sterilizers
--------------------------------------------------------------------------------------------------------
DRYING CABINET                     Lancer                      175        Common
--------------------------------------------------------------------------------------------------------
WASH RACK, W/LONG JETS             Lancer                      175        Common
--------------------------------------------------------------------------------------------------------
WASHER/DRYER, GLASSWARE            Lancer                      175        Common
 W/ACCESSORI
--------------------------------------------------------------------------------------------------------
COMPUTER & MONITOR 4020SX          Tandy                       187        Growth
 2MB                                                                      Chambers
--------------------------------------------------------------------------------------------------------
GROWTH CHAMBER                     Gaffney Engineering         187        Common
--------------------------------------------------------------------------------------------------------
GROWTH CHAMBER                     Gaffney Engineering         187        Common
--------------------------------------------------------------------------------------------------------
PALLET JACK, 8" WHEEL DAYTON       Datco Inc.                  187        Common
--------------------------------------------------------------------------------------------------------
SAFETY CABINET-CHEMICAL            Fisher Scientific           187        Common
--------------------------------------------------------------------------------------------------------
REFRIGERATOR, 18CUFT W/ICEM        Kenmore                     0116A      Common
--------------------------------------------------------------------------------------------------------
CENTRIFUGE-MICRO, BENCHTOP         Eppendorf                   147A       Common
--------------------------------------------------------------------------------------------------------
X-RAY MACHINE                                                  174        Common        Predation
--------------------------------------------------------------------------------------------------------
</TABLE>

LIFE SCIENCES INC.
ENZYME PRODUCTION CONTINGENCY PLAN                                           A-5
<PAGE>   26
                            BDI COMMON USE EQUIPMENT

<TABLE>
---------------------------------------------------------
<S>               <C>      <C>      <C>      <C>
LCD PROJECTOR     Epson    114A     Common   Karan Dundas
---------------------------------------------------------
30" TV w/VCR      Sharp    144A     Common
---------------------------------------------------------
CD RECORDER                187      Common   Bryan Almira
---------------------------------------------------------
</TABLE>

LIFE SCIENCES INC.                                                           A-6

ENZYME PRODUCTION CONTINGENCY PLAN
<PAGE>   27
                                   APPENDIX 2
                           BDI SPACE ALLOCATION PLAN

                                     [MAP]

                                 Licensed Space

                                Available Space

LIFE SCIENCES INC.

ENZYME PRODUCTION CONTINGENCY PLAN
<PAGE>   28

[UNIVERSITY OF FLORIDA LETTERHEAD]
SID MARTIN BIOTECHNOLOGY DEVELOPMENT INSTITUTE              12085 Research Drive
                                                          Alachua, FL 32615-6832
                                                                  (904) 462-0880
                                                              Fax (904) 462-0875

26 August, 1999

Alex Burns
Life Sciences, Inc.
2900 72nd Street North
St. Petersburg, FL 33710

Dear Alex;

The BDI is glad to be able to provide contingency support for LSI as an
associate member of the Biotechnology Development Institute. For your future
planning, you should be aware that here is no term or renewal limit connected
with this program. Yearly extension requests from LSI for participation in the
associate Membership program through the year 2002 will be granted, provided
that LSI meets all requirements set forth in the original Associate Membership
Agreement and in the Guidelines for Qualification established by the BDI on a
yearly basis.

Sincerely,

/s/ William J. Dinehart
William J. Dinehart
Incubator Manager

               EQUAL OPPORTUNITY / AFFIRMATIVE ACTION INSTITUTION
<PAGE>   29

(UNIVERSITY OF FLORIDA LETTERHEAD)
<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------
<S>                                                                              <C>
Biotechnology Program                                                                         PO Box 110580
     Interdisciplinary Center for Biotechnology Research (ICBR)                  Gainesville, Florida 32611
     Biotechnology Development Institute (BDI)                                          Tel: (352) 392-8408
                                                                                        Fax: (352) 392-8598
</TABLE>

March 10, 1999

Mr. Alex Burns,
Vice President
Life Sciences Inc.
2900 72nd Street North
St. Petersburg, Florida 33710

Dear Alex,

         Thank you for your recent inquiry regarding Life Sciences use of the
resources at the Sid Martin Biotechnology Development Institute (BDI) as a
contingent manufacturing facility for its critical enzyme products in the
unlikely event of a catastrophic loss of your existing facilities. Since one of
the key elements of the Institute's primary mission is to foster the
development of the entrepreneurial biotechnology industry in the State of
Florida, we believe that the proposal that you have made is consistent with our
goals, and it would be appropriate for us to provide contingency support to you
in an emergency.

         In your earlier correspondence, you provided a short list of equipment
that you would acquire and install in the BDI in order to complement the common
equipment that would be available to you as an Associate Member. We believe it
will be possible to find suitable floor space, and the 25 linear feet of bench
space you have indicated you will require without difficulty. As it is
impossible for us to identify the specific space that might be available in the
event of an emergency, you should be aware that some areas of our facility are
only supplied with single-phase 115/220 volts ac power. In the event that your
installations require 3 phase power or current in excess of 50 amps on a single
circuit, LSI will be required to pay for the renovations necessary to provide
access to special voltage/current/or phase combinations at a specific location.

         The (3)H-isotope work area that you will require will need to be
contained in the emergency space provided to LSI by the Institute. You should
be aware that all members of your staff who participate in operations in this
facility would be required to successfully complete the University's radiation
safety program before commencing any operations in this facility. In addition,
all operations involving the use of radioisotopes that take place in the BDI
will be subject to the rules and regulations of the University of Florida's
radiation safety office, and be subject to the same controls and limitations
required of the BDI's resident incubator program licensees.

                Equal Opportunity/Affirmative Action Institution

<PAGE>   30

         I believe that LSI's participation in the Associate Member Program is a
suitable vehicle to accommodate our agreement to provide emergency production
space, as well as the off-site storage component of your contingency plan.
However, in the event that LSI is forced to activate its contingency production
plan, LSI will be required to pay a $20 per square foot annual charge for the
space provided to LSI during the emergency period, and prorated for the time the
space is actually utilized by LSI. The BDI will only be able to guarantee LSI
the use of such space for six months following the activation of its contingency
production plan. If LSI should need more than six months, sixty days prior to
the end of that term, LSI and the BDI's administration will review LSI's
operations at the incubator and evaluate whether an extension to the initial
term is feasible.

         As you know, we have over the years explored a variety of potential
paths to bring Life Sciences into participation with the University's
biotechnology programs. Your proposal regarding contingent manufacturing is a
good first step. We are, however, very intrigued with your ongoing work on
rapid detection of environmental pathogens using NASBA and the potential impact
of this technology on a variety of bioscience related research and development
programs being carried out by affiliates of the Institute as well as by
University faculty and staff. We look forward to a more active participation of
LSI in the University's activities.

Sincerely,

/s/ Sheldon M. Schuster, Ph.D.

Sheldon M. Schuster, Ph.D.
Professor and Program Director

<PAGE>   31

(UNIVERSITY OF FLORIDA LETTERHEAD)

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------
<S>                                                                 <C>
SID MARTIN BIOTECHNOLOGY DEVELOPMENT INSTITUTE                         12085 Research Drive
                                                                     Alachua, FL 32615-6832
                                                                             (904) 462-0880
                                                                         Fax (904) 462-0875

</TABLE>

                         BDI ASSOCIATE MEMBER AGREEMENT

between                                               and
University of Florida Research Foundation, Inc.       Life Sciences, Inc.
University of Florida                                 2900 72nd Street North
109 Grinter Hall                                      St. Petersburg, FL 33710
Gainesville, Florida 32611

I.       This agreement is made as of the 1st day of July, 1999, the effective
date, between representatives of the parties named above: This agreement is for
the purpose of the development of mutually beneficial biotechnology business
collaborations and is subject to the terms and conditions contained herein.
These parties have a mutual interest in the advancement of Life Sciences,
Inc.'s business and scientific goals, and the development of the biotechnology
industry in Florida, which is the basis for this agreement. In particular, the
UFRFI wishes to assist Life Sciences, Inc. (LSI), with implementation of its
contingency plan, to enable it to sustain production of enzymes in the event of
a catastrophic loss of its primary facilities.

II.      In furtherance of this agreement, the UFRFI agrees to:

         a)       Provide limited and prioritized access to the facilities of
                  the BDI including common use scientific equipment specified by
                  LSI, meeting space, and related infrastructure under the terms
                  and conditions in accordance with, and outlined in, section
                  III and section IV of this agreement.

                  1.       Allow a Life Sciences -85(degree)C cryogenic
                           storage cabinet, as described in exhibit A attached
                           hereto, to be located at the BDI for storage of small
                           quantities (less than 1000 grams) of frozen pellets
                           of avian myeloblastosis virus and E.coli.
                  2.       Provide, on a space available basis, in the event
                           that Life Sciences needs to implement the contingency
                           plan, sufficient work space for two technicians, a
                           source of 200L/day of high purity water, and
                           twenty-five linear feet of lab counter space, and
                           ready access to a walk-in cold room for protein
                           purification.
                  3.       In the event that the contingency plan referred to
                           above must be implemented, and before contingency
                           space can be occupied, LSI will be required to sign a

               Equal Opportunity / Affirmative Action Institution
<PAGE>   32
                         separate Incubator Licensing Agreement (ILA) a true
                         copy of which is attached hereto as exhibit 'B',
                         provide liability insurance as specified in the ILA,
                         and pay an occupancy fee of $200 as well as a $20 per
                         square foot per year Licensee fee during the emergency
                         period.
                 4.      The UFRFI will provide LSI the use of such space for
                         six months following the activation of its contingency
                         production plan, and the execution of the ILA. Sixty
                         days prior to the end of that term, LSI and the BDI
                         administration will review LSI's operations at the
                         incubator and evaluate whether an extension to the
                         initial term is warranted.

        b)       Provide limited and prioritized access to the BDI library,
                 computer facilities, and business assistance services as
                 outlined and in accordance with section IV below.
        c)       Provide access to the Core Facilities of the Interdisciplinary
                 Center for Biotechnology Research through its commercial
                 subsidiary, The Comprehensive Biotechnology Resource, at a
                 special Associate Member rate.
        d)       Provide limited access to BDI Internet services.

III.    The LSI agrees to:

        a)       Pay a nonrefundable annual Associate Member Fee in the amount
                 of $2000.00, payable to the University of Florida Research
                 Foundation Inc. and due on or before the commencement date of
                 this agreement. Return the above fee as well as this executed
                 agreement to the Biotechnology Development Institute, 12085
                 Research Drive, Alachua, FL 32615. Checks must be made payable
                 to the University of Florida Research Foundation, Inc.
        b)       Make a good faith effort to use the BDI services and facilities
                 specifically and exclusively for the advancement of its
                 business development goals and those of the BDI members, as
                 outlined in the Associate Member Application.
        c)       Comply with all applicable UFRFI and University rules and
                 policies, including without limitation, the guidelines and
                 policies of the University Division of Environmental Health and
                 Safety.
        d)       Execute the Assumption of Risk, Waiver of Liability and Hold
                 Harmless Agreement attached hereto as exhibit 'C' regarding the
                 placement and maintenance of LSI's cryogenic storage cabinet on
                 UFRFI premises.

IV.     The parties mutually agree that:

        a)       The program shall be conducted by the Biotechnology
                 Development Institute in accordance with the laws, rules and
                 regulations of the State of Florida, the Board of Regents, the
                 State University System and the University of Florida.
        b)       The effective period of this agreement commences on July 1,
                 1999 and will end on June 30, 2000.
        c)       Continued annual participation in the program is at the sole
                 discretion of the BDI and the Biotechnology Program
                 administration. This agreement may be terminated by UFRFI upon
                 written notice to LSI. The agreement may be renewed or extended
                 by written mutual agreement of the parties.

<PAGE>   33
         d)       Access to BDI services and facilities will be restricted to
                  available resources and at a lower priority, available only
                  after the BDI's primary commitments to its licensee companies
                  have been met.
         e)       LSI will have no permanent space assignment within the BDI.
                  Access to the BDI and its infrastructure and services is
                  limited to normal working hours.
         f)       No advertising, publicity or news release containing any
                  reference to the Biotechnology Development Institute or the
                  University of Florida or LSI shall be used by either party
                  without mutual agreement.

For UFRFI:                                 For LSI:

/s/ Dr. Thomas Walsh     7-10-99           /s/  Alex Burns           1 July 99
----------------------------------         ------------------------------------
Dr. Thomas E. Walsh        Date            Alex Burns                  Date
President, UFRFI                           Vice President, Life Sciences, Inc.

<PAGE>   34

                                   Attachment

                             EQUIPMENT AND SERVICES

Life Sciences's Revco -85(degree)C upright cryogenic storage cabinet model
number A850SUF-14, serial number 217H414421 to be located at the BDI
<PAGE>   35
                              GENERAL COVER POLICY

NO. ZG 0014220                                                            [LOGO]

                       PACIFIC INSURANCE COMPANY, LIMITED
                              Hartford, Connecticut

ZG 0011814
--------------
Renewal of No.

           SEND CORRESPONDENCE TO: PACIFIC INSURANCE COMPANY, LIMITED
                    C/O: FIRST STATE MANAGEMENT GROUP, INC.
              150 FEDERAL STREET, BOSTON, MASSACHUSETTS 02110-1753

                                                       RICHARD F. HULL
                                                Surplus Lines Agent #A125683
                                            This insurance is issued pursuant to
                                                the Florida Surplus Lines Law

INSURED'S NAME AND ADDRESS:      (NO., STREET, TOWN, COUNTY, STATE)
LIFE SCIENCE INC & LIFE SCIENCES ENVIRONMENTAL INC

Post Office Box 48039

St. Petersburg, FL 33743

                                     "Persons insured by Surplus Lines Carriers
                                     do not have the protection of the Florida
                                     Insurance Guaranty Act to the extent of any
                                     Right of Recovery for the obligation of an
                                     Insolvent Unlicensed Insurer"

POLICY PERIOD:                   (MO. DAY YR.)
FROM JUNE 5, 1999 to JUNE 5, 2000

$                    PREMIUM      --         RATE $ See Declarations  AMOUNT
 ------------------         ----------------        -----------------

IN CONSIDERATION OF THE STIPULATIONS HEREIN NAMED AND OF THE PREMIUM ABOVE
SPECIFIED THE COMPANY DOES INSURE THE INSURED NAMED ABOVE, HEREINAFTER CALLED
THE INSURED, WHOSE ADDRESS IS SHOWN ABOVE, FROM THE INCEPTION DATE SHOWN ABOVE,
AT 12:01 A.M. (STANDARD TIME), TO THE EXPIRATION DATE SHOWN ABOVE, AT 12:01
A.M., STANDARD TIME AT PLACE OF ISSUANCE, TO AN AMOUNT NOT EXCEEDING THE
AMOUNT(S) ABOVE SPECIFIED, ON THE FOLLOWING DESCRIBED PROPERTY:

         DO NOT ASSIGN ADJUSTER                      Policy Fee:
IN CASE OF LOSS, REFER NOTICE IMMEDIATELY            State Tax:
           TO CLAIMS MANAGER                         Florida Service Fee:
   FIRST STATE MANAGEMENT GROUP, INC.                Emergency Fund:
 150 FEDERAL ST., BOSTON, MA 02110-1753
C-225 (4/92)  617-526-7600

                                                     Total Policy Premium:

SUBJECT TO FORM NO(S). XP 00 55 03 96 Supplemental Declarations, IL0017(11/85),
CP0090(7/88), ATTACHED HERETO:

CP0010(6/95), CP1030(6/95), CP0030(6/95), IL0935(8/98), IL0255(3/98),
IL0175(9/93), PC-21(5/96), PS-2, PS-1(9/93), PM-3(35%), C-142, C-185(10/95),
CP1210(11/85), CP0440(6/95), XP9911(11/93), Endorsement 1

THIS POLICY IS MADE AND ACCEPTED SUBJECT TO THE FOREGOING PROVISIONS AND
STIPULATIONS AND THOSE HEREINAFTER STATED, WHICH ARE HEREBY MADE A PART OF THIS
POLICY, TOGETHER WITH SUCH OTHER PROVISIONS, STIPULATIONS AND AGREEMENTS AS MAY
BE ADDED HERETO, AS PROVIDED IN THIS POLICY.

                                       ATLANTA, GEORGIA

                                       /s/ Vera Edle Miller
                                       ---------------------------
COUNTERSIGNED: VEM/bjw   06/29/99      COUNTERSIGNATURE

FORM XP 00 31 05 97
<PAGE>   36
[LOGO]   EVANSTON INSURANCE COMPANY                         Policy No. MC800569
         SHAND MORAHAN PLAZA                                Prev. No.  MC800212
         EVANSTON, ILLINOIS 60201                           Prod. No.  HF202

DECLARATIONS -    GENERAL LIABILITY INCLUDING PRODUCTS/COMPLETED OPERATIONS
                  (CLAIMS MADE)

Claims Made Policy: This Policy is limited to liability for only those CLAIMS
THAT ARE FIRST MADE AGAINST THE INSURED DURING THE POLICY PERIOD. Please review
the policy carefully.

1.       NAMED INSURED: LIFE SCIENCES, INC. & LIFE SCIENCE ENVIRONMENTAL, INC.

2.       BUSINESS ADDRESS OF THE INSURED:             RICHARD F. HULL
             P.O. BOX 48039                    Surplus Lines Agent #A125683
             ST. PETERSBURG, FL 33743       This insurance in issued pursuant to
                                               the Florida Surplus Lines Law

3.       POLICY PERIOD: From June 5, 1999 to June 5, 2000
                        12:01 A.M. Standard Time at address of Insured stated
                        above.

4.       LIMITS OF LIABILITY: COMBINED SINGLE LIMIT Bodily Injury and Property
         Damage Liability

                  All claims from each occurrence;                 $1,000,000

                  Policy aggregate                                 $1,000,000

5.       DEDUCTIBLE:

         Applicable to each occurrence, including claim expenses   $    2,500

6.       SPECIFIED PRODUCTS, OPERATIONS AND PREMISES COVERED: Laboratory
         Development of enzymes, primarily transcriptase used in Labs for DNA
         Research

         Manufactured by the Insured including all premises and operations of
         the Named Insured which are normal or incidental thereto.

                                                      "Persons insured by
                                                      Surplus Lines Carriers
                                                      do not have the protection
                                                      of the Florida Insurance
                                                      Guaranty Act to the extent
7.       RETROACTIVE DATE: June 5, 1998               of any Right of Recovery
                                                      for the obligation of an
8.       RATE: Adjustable at $3.79 per $1,000         Insolvent Unlicensed
         Gross Sales                                  Insurer"

9.       PREMIUM FOR POLICY PERIOD:

                  Annual Minimum                                   $
                  Deposit                                          $
                  Policy Fee                                       $
                  State Tax 5%                                     $
                  Service Fee .3%                                  $
                  Total Policy Premium:                            $

10.      PREMIUM FOR EXTENDED DISCOVERY PERIOD: (SEE ENDORSEMENT NO. 5)

                                    Page -1-
<PAGE>   37

11. ENDORSEMENTS ATTACHED:

    1. Year 2000 Exclusion Endorsement
    2. Endorsement - Broadening Endorsement - EIC 831 12/88
    3. Endorsement - Asbestos Exclusion - EIC 832 1/89
    4. Claim Expenses in Addition to the Limits of Liability
    5. GL/CompOps Option to purchase OEP

                                           ALL CLAIMS TO BE REPORTED DIRECTLY TO

                                           Shand Morahan & Company, Inc.
                                           Shand Morahan Plaza
                                           Evanston, Illinois 60201
                                           (847) 868-2800

                                           /s/
                                          --------------------------------------
                                                (Authorized Representative)

Policy Form: (CGL-EIC 844) 12/92
EIC 1 DEC 2/93
Date Printed: July 2, 1999

                                    Page -2-

<PAGE>   38

================================================================================

                         SUPPLEMENTAL DECLARATIONS PAGE

POLICY NO.        ZG 0014220

POLICY PERIOD     JUNE 5, 1999               TO       JUNE 5, 2000

NAMED INSURED

===================================================================
LIFE SCIENCE INC & LIFE SCIENCES ENVIRONMENTAL INC
Post Office Box 48039
St. Petersburg, FL 33743

<TABLE>
<CAPTION>
DESCRIPTION OF PREMISES
==================================================================================================================================
PREM NO.   BLDG. NO.     LOCATION, CONSTRUCTION AND OCCUPANCY
<S>        <C>           <C>
 1           1-2         2900 72nd Street North, St. Petersburg, FL 33743

 2            1          12085 Research Drive, Alachua, FL 32615

                         Above are modified fire resistive construction, occupied as enzyme development lab - organic chemistry.
</TABLE>

<TABLE>
<CAPTION>
COVERAGES PROVIDED INSURANCE AT THE DESCRIBED PREMISES APPLIES ONLY FOR COVERAGES FOR WHICH A LIMIT OF INSURANCE IS SHOWN.
==================================================================================================================================
PREM NO.   BLDG. NO.       COVERAGE                LIMIT OF INSURANCE           COVERED CAUSES OF LOSS      COINSURANCE*     RATES
<S>        <C>             <C>                     <C>                          <C>                         <C>              <C>
 1            1            Building                   $1,200,000.                         Special               90%          .348
                           Personal Property          $  150,000.                                               90%
 1            2            Building                   $1,200,000.                                               90%
                           Personal Property          $  700,000.                                               90%
                           Business Income with       $  300,000.                                               50%
                             Extra Expense
 2            1            Personal Property          $  100,000.                                               90%
                                                                                 *IF EXTRA EXPENSE COVERAGE LIMITS ON
                                                                                 PAYMENT
</TABLE>

<TABLE>
<CAPTION>
SUB-LIMIT: Food Spoilage - See Form #CP0440 (6/95).
OPTIONAL COVERAGES APPLICABLE ONLY WHEN ENTRIES ARE MADE IN THE SCHEDULE BELOW
==================================================================================================================================
PREM NO.   BLDG. NO.  AGREED VALUE                      REPLACEMENT COST(X)
                      EXPIRATION DATE      AMOUNT       BUILDING                 PERSONAL PROPERTY          INCLUDING STOCK
<S>        <C>        <C>                  <C>          <C>                      <C>                        <C>
1-2        ALL         N/A                 N/A                X                          X                      N/A
</TABLE>

<TABLE>
<S>                                          <C>                             <C>                      <C>
                                             *MONTHLY LIMIT OF               *MAXIMUM PERIOD            *EXTENDED PERIOD
                                             INDEMNITY (Fraction)            OF INDEMNITY (X)         OF INDEMNITY (DAYS)
                                                   N/A                             N/A                        N/A

MORTGAGE HOLDERS                                               *APPLIES TO BUSINESS INCOME ONLY
==================================================================================================================================
PREM NO.  BLDG. NO.   MORTGAGE HOLDER NAME AND MAILING ADDRESS

                      N/A

DEDUCTIBLE
==================================================================================================================================

WIND, HAIL, WIND DRIVEN WATER, COLLAPSE DUE TO WIND, AND ANY OTHER WIND RELATED PERILS - 2% Values at time and place of loss
subject to $25,000, Minimum Per Occurrence.
ALL OTHER PERILS - $5,000, Per Occurrence.

FORMS APPLICABLE
==================================================================================================================================
TO ALL COVERAGES           SEE FORM XP 00 31 05 97 FOR FORMS AND ENDORSEMENTS
TO SPECIFIC PREMISES COVERAGES
PREM NO. BLDG. NO.    COVERAGES                       FORM NUMBER
</TABLE>

<PAGE>   39
POLICY NUMBER: ZG 0014220                                    COMMERCIAL PROPERTY
                                                                  CP 04 40 06 95

         THIS ENDORSEMENT CHANGES THE POLICY. PLEASE READ IT CAREFULLY.

                               SPOILAGE COVERAGE

This endorsement modifies insurance provided under the following:

     BUILDING AND PERSONAL PROPERTY COVERAGE FORM
     CONDOMINIUM COMMERCIAL UNIT-OWNERS COVERAGE FORM

<TABLE>
<CAPTION>
                                                               SCHEDULE*

                                                                                                      CAUSES OF LOSS:
                            DESCRIPTION                                        REFRIGERATION      BREAKDOWN
PREM.         BLDG.            OF              LIMIT OF                         MAINTENANCE          OR            POWER     SELLING
 NO.           NO.          PROPERTY          INSURANCE       DEDUCTIBLE          AGREEMENT      CONTAMINATION     OUTAGE     PRICE
-----        ------         -----------       ----------      ----------       -------------     -------------     ------    -------
<S>          <C>            <C>               <C>             <C>              <C>               <C>               <C>       <C>
 1             2            Personal          **$200,000.     $ 5,000.              N/A               N/A             X        N/A
                            Property
</TABLE>

** Sub-Limit

<TABLE>
<S>                                                                             <C>
The Coverage Form to which this endorsement applies is                          B. The following is added to Paragraph A
extended to insure against direct physical loss or                                 PROPERTY NOT COVERED:
damage by the Covered Causes of Loss, but only with                                  9. Property located:
respect to coverage provided by this endorsement.                                       (1) On buildings;
A. Paragraph A.1. COVERED PROPERTY is replaced                                          (2) In the open; or
   by the following:                                                                    (3) In vehicles.
   1. Covered Property
      Covered Property means "perishable stock" at
      the described premises owned by you or by
      others that is in your care, custody or
      control.
</TABLE>

* Information required to complete this Schedule, if not shown on this
  endorsement, will be shown in the Declarations.

CP 04 40 06 95   Copyright ISO Commercial Risk Services, Inc., 1994      Page 1

<PAGE>   40

                                                           Hy-Line International
                                                                    P.O. Box 309
                                                                    4432 Hwy 213
                                                             Mansfield, GA 30055

                                                                 24 August, 1999

Jordan Brown Kang
Production Manager
Life Sciences, Inc.
2900 72nd Street North
St. Petersburg, FL. 33710

Dear Mr. Kang,

We are pleased to inform you that Hy-Line International intends to continue its
operations in the poultry breeding industry and ensuring the availability of
W-36 eggs and chickens for Life Sciences, Inc. at least to the year 2003.

                                                      /s/<PAGE>   1

                                                                  Exhibit 10.16

                         FACILITIES OPERATION AGREEMENT

THIS FACILITIES OPERATION AGREEMENT (the "Agreement") is made as of May 25th,
2000, between LIFE SCIENCES, INC. a Delaware corporation ("LSI") and ORGANON
TEKNIKA B.V., a private company with limited liability, incorporated under the
laws of The Netherlands ("TEKNIKA"), and is made with reference to the
following facts:

         (A) On or about May 25th, 2000, LSI and TEKNIKA entered into a Supply
Agreement (the "Supply Agreement") wherein LSI agreed to supply to TEKNIKA the
"Products" (as defined therein). All terms and provisions of the Supply
Agreement are incorporated in this Agreement by this reference.

         (B) The Supply Agreement, among other things, requires LSI to provide
certain amounts of Products to TEKNIKA (the "Products Requirements") in a timely
manner. Should LSI fail to fulfill the requirements as described in the Supply
Agreement, TEKNIKA desires to be granted the right to: (i) introduce a person of
its own selection into LSI's production facilities to direct the utilization of
such property and employees of LSI as are necessary or appropriate to cause the
Products Requirement to be fulfilled in accordance with the Supply Agreement;
and (ii) receive from LSI a license of certain "know how"; and a right to
purchase a bulk quantity of avian myeloblastosis virus (AMV); a quantity of AMV
suitable for innoculum into avian hosts to produce additional virus; and seed
cultures of relevant bacterial strains that will enable it to produce the
required amounts of some of the Products. To accomplish the foregoing, on or
about the date hereof, LSI, as licensor, and TEKNIKA, as licensee, have entered
into a license agreement wherein such "know how" is licensed from LSI to TEKNIKA
(the "License Agreement"). All terms and provisions of the License Agreement are
incorporated in this Agreement by this reference.

         (C) The parties intend this Agreement to be effective only upon the
failure of LSI to meet TEKNIKA's periodic requirements for Products as required
by the Supply Agreement. As such, this Agreement shall only become effective
upon a "Triggering Event", as defined below.

         (D) Assuming a Triggering Event has occurred, the purpose of this
Agreement is to grant from LSI to TEKNIKA the right to have access to and
utilize the resources of LSI necessary to insure the fulfillment of the Products
Requirement.

         NOW, THEREFORE, for and in consideration of the premises and the mutual
covenants and agreements herein, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, LSI and TEKNIKA agree
as follows:

         1.       RECITALS. The recitals of facts set forth above are true and
correct and are by this reference made a part thereof.
<PAGE>   2
         2.      FACILITIES OPERATION.  Upon the occurrence of a Triggering
Event, the following rights and obligations as between the parties hereto shall
immediately arise:

                  (a)      Written Notice. In the event LSI is unable or
unwilling to manufacture or supply the Products as required by the Supply
Agreement ("Triggering Event"), the Contingency Plan, as defined in the Supply
Agreement of which this Agreement forms a part, may be invoked by Teknika in
accordance with Article 11.2 of the Supply Agreement. Teknika will notify LSI
that it considers that a Triggering Event has occurred.

                  (b)      Effectiveness of Agreement. On the fifth (5th)
business day following LSI's receipt of written notice of the Triggering Event,
and assuming LSI does not dispute the veracity of TEKNIKA's notice of a
Triggering Event, this Agreement is required to be executed and delivered.

                  (c)      Purchase Order from Teknika. Upon the effectiveness
of this Agreement and the License Agreement, TEKNIKA shall immediately send to
LSI a purchase order for four hundred and fifty (450) grams of AMV at $427.00
per gram (the "AMV Purchase Order"). Upon LSI's receipt of the AMV Purchase
Order, it shall immediately cause to be available for pick up by TEKNIKA or its
representatives at LSI's property all of the AMV that it has on site up to 450
grams. Upon the tendering of such AMV, TEKNIKA shall pay for the full amount of
AMV delivered at the price indicated above, in cash or cash equivalent.

                  (d)      TEKNIKA Supervision. Upon LSI's receipt of the
payment the AMV described in subsection (c) next above, LSI shall immediately
make available a portion of its premises whereby an authorized representative
of TEKNIKA (the "TEKNIKA Representative") may oversee the future short term
production of Products by LSI, all to be performed in accordance with the terms
and provisions of the Supply Agreement. The following guidelines shall govern
the conduct of the TEKNIKA Representative while he or she is on site at LSI's
property:

                           (i)      The TEKNIKA Representative may only have
access to the portions of LSI's property that are necessary for TEKNIKA to
confirm that the Product is being generated, as determined by the "Know How"
provided under the License Agreement.

                           (ii)     To the extent the TEKNIKA Representative
makes changes to the know how that is being licensed to TEKNIKA under the
terms of the License Agreement:

                                    (A)      TEKNIKA shall pay to LSI upon
demand all increased costs of production associated with the Products that
would not otherwise have been incurred, but for the TEKNIKA Representative's
changes to the procedures and protocol for production of the Products; and

                                                                               2
<PAGE>   3

                                    (B)      TEKNIKA assumes all liability,
obligation and responsibility for any changes to the Products resulting from
TEKNIKA Representative's changes to the "Know How" obtained through the License
Agreement.

         3.       TERM. The term of this Agreement shall begin as defined in
paragraph 2(b). Upon resumption of the manufacture of the Products at a level
sufficient to fulfill the Product Requirement, LSI shall notify TEKNIKA in
writing of the termination of this Agreement (a "Termination Notice"). Upon LSI
tendering the Termination Notice to TEKNIKA, the parties shall immediately take
such actions as are reasonably necessary to wind up this Agreement, including,
without limitation, the removal of all raw materials for the production of the
Products owned by TEKNIKA from LSI's property, the removal of the TEKNIKA
Representative from LSI's property, and a final accounting shall be generated
by LSI of the Production Costs (as defined below). Upon payment of all such
sums, this Agreement shall automatically revert to a standby status without
further action by any party hereto.

         4.       PRODUCTION COSTS. In consideration of the rights granted to
TEKNIKA under this Agreement, TEKNIKA hereby agrees to pay to LSI the price for
the Products manufactured under the terms of this Agreement, as set forth in
the Supply Agreement, less the value of the avian myeloblastosis virus
component used to produce such Products and previously purchased by TEKNIKA
from LSI. TEKNIKA shall pay to LSI the adjusted price for the Products within
15 business days of LSI's invoice for the Products.

         5.       LIMITATION AND INDEMNITY. LSI shall not be liable to TEKNIKA,
or any of its agents, employees, servants or invitees, including the TEKNIKA
Representative (collectively the "TEKNIKA Parties") for any injury to persons
or damage to property due to the condition of LSI's property which may exist or
subsequently occur, and TEKNIKA, with respect to itself and the TEKNIKA
Parties, hereby expressly assumes all risks and injury to persons and damage to
property, either proximate or remote by reason of the present or future
condition of such property. TEKNIKA agrees that it will indemnify and hold
harmless LSI from and against all suits, claims and actions of every kind by
reason of any breach, violation or nonperformance of any term or conditions on
the part of TEKNIKA hereunder. Additionally, TEKNIKA agrees to indemnify and
hold LSI harmless from and against all claims, actions, damages, liabilities
and expenses asserted against LSI on account of injuries to persons or damage
to property when and to the extent that any such damage or injury may be
caused, either proximately or remotely, wholly or in part by any act or
omission, whether negligent or not, of TEKNIKA and the TEKNIKA Parties,
contractors, patrons or invitees or of any other person entering on LSI's
property under or with the expressed or implied invitation of TEKNIKA, or if
any such injury or damage may in any other way arise from or out of the
occupancy or use by the TEKNIKA Parties of LSI's property. This paragraph is
for the benefit of LSI only, and no right of action shall accrue hereunder to
any third party by way of subrogation or otherwise.

         6.       DEFAULT

                  (a)      Any of the following events shall be deemed to be an
event of default by TEKNIKA under this Agreement:

                                                                               3
<PAGE>   4
                           (i)      TEKNIKA shall fail to make any payment
                  required under this Agreement within five (5) days after it is
                  due.

                           (ii)     The License Agreement shall be terminated.

                           (iii)    TEKNIKA shall become insolvent, or shall
                  make a transfer in fraud of creditors or shall make an
                  assignment for the benefit of creditors.

                           (iv)     TEKNIKA shall file a petition under any
                  bankruptcy act, or under any similar law or statute of any
                  jurisdiction.

                           (v)      There shall be filed against TEKNIKA an
                  involuntary petition in bankruptcy or insolvency or a similar
                  proceeding, and such filing or proceeding shall not be
                  dismissed within ninety (90) days.

                           (vi)     A receiver or trustee shall be appointed for
                  all or substantially all of the assets of TEKNIKA or for the
                  assets of TEKNIKA which utilize the Products.

                           (vii)    TEKNIKA's interest under this Agreement is
                  sold under execution or other legal process.

                  (b)      Upon the occurrence of an event of default, LSI, in
addition to all other rights or remedies that may have, shall have the right to
immediately terminate this Agreement, and dispossess TEKNIKA, and the TEKNIKA
Representative, of its license to be on LSI's property, and to also terminate
the License Agreement and all other aspects of this Agreement.

If LSI at any time terminates this Agreement for any breach, in addition to
other remedies, LSI may recover from TEKNIKA all damages it may incur by reason
of such breach, including reasonable attorney's fees, all of which amounts
shall be immediately due and payable from TEKNIKA to LSI.

         7.       GENERAL.

                  (a)      This Agreement embodies as refers to the entire
         agreement between the parties hereto relative to the subject matter
         hereof and shall not be modified, changed, or altered in any respect
         except in writing. Where the terms of this Agreement conflict with the
         terms of the Supply Agreement or the License Agreement, the terms of
         this Agreement will prevail.

                  (b)      The covenants, agreements, and obligations herein
         contained shall extend to, bind, and inure to the benefit not only of
         the parties hereto but their successors and assigns.

                  (c)      Any notice, request, demand or other communication
         which is required or may be given under this Agreement shall be in
         writing and shall be deemed to have

                                                                               4
<PAGE>   5
         been duly given: (i) if transmitted by telecopy, electronic telephone
         line facsimile transmission or other similar electronic or digital
         transmission method, when transmitted; (ii) if sent by a nationally
         recognized next day delivery service that obtains a receipt on delivery
         the day after it is sent; (iii) if mailed, first class registered or
         certified mail, postage prepaid, 3 days after it is sent or when
         actually received, whichever is sooner; and (iv) in any other case,
         when actually received. All notices to be given hereunder shall be
         given as follows:

If to LSI:                 Alex Burns
                           Vice President
                           Life Sciences, Inc.
                           2900 72nd Street North
                           St. Petersburg, Florida 33710
                           Facsimile: (727) 347-2957

If to TEKNIKA:             Robert van Geffen
                           Organon Teknika B.V.
                           Boseind 15,5281
                           RM Boxtel, The Netherlands
                           Facsimile: 31-411-654-193

         8.  GOVERNING LAW. This Agreement is to be construed under the laws of
the State of Florida. Should any provisions of this Agreement and/or of its
conditions be illegal or unenforceable under any court decision or any laws,
ordinances or regulations of any governing authority having jurisdiction over
the parties hereto, it or they shall be considered severable, and all other
provisions of this Agreement shall remain in full force and be binding upon the
parties as though the illegal or unenforceable provisions had never been
included. The venue for any action hereunder shall be Pinellas County, Florida.
English shall be the official language of this Agreement.

         9.  DISPUTE RESOLUTION.

             (a) The parties shall attempt in good faith to resolve promptly
any dispute arising out of or relating to this Agreement by negotiation. If the
matter can not be resolved in the normal course of business, any interested
party shall give the other party written notice of any such dispute not
resolved, after which the dispute shall be referred to more senior executives of
both parties, who shall likewise attempt to resolve the dispute.

             (b) If the dispute has not been resolved by negotiation within
forty-five (45) days of the disputing party's written notice, or if the parties
fail to meet with twenty (20) days as from such notice, the parties shall
endeavor to settle the dispute by binding arbitration under the then prevailing
rules of the American Arbitration Association. The arbitration shall be
conducted in St. Petersburg, Florida.

             This paragraph shall, however, not be construed to limit or to
preclude either party from bringing any action in any court of competent
jurisdiction for injunctive or other provisional relief as necessary or
appropriate.

         10.  SECTION HEADINGS. The section headings of this Agreement are for
convenience

                                                                               5
<PAGE>   6
only and shall not be considered in the interpretation of the terms and
provisions of this Agreement.

         11.      CONFIDENTIALITY. The parties hereto agree that the
confidentiality standards and that are contained in the Supply Agreement are
incorporated in this Agreement by this reference.

         IN WITNESS WHEREOF, the parties have executed this Agreement the day
and first above written.

LSI

LIFE SCIENCES, INC.,

By: /s/ Alex Burns
   -------------------------------------------
        Alex Burns
        Its Vice President

(CORPORATE SEAL)

TEKNIKA:

ORGANON TEKNIKA B.V.

By: /s/ Dr. R. Salsmans
   -------------------------------------------
        Dr. R. Salsmans, President

By: /s/ A.J.F. Stap
   -------------------------------------------
        A.J.F. Stap, Executive Vice President

(CORPORATE SEAL)

                                                                               6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]